



The Pharmaceutical Research Institute at Albany College of Pharmacy is an R&D institute developed by New York State's oldest pharmacy school, one of the only independent, private pharmacy schools in the United States. The Institute is dedicated to a three-pronged business development model focused on **research, pharmaceutical services** and **education** in partnership with industry and academic and research centers in New York State's Capital Region and beyond.

PRI strives to advance pharmaceutical science through its own novel discovery as well as its collaborative efforts with research partners across town and across the globe. Through all of its components, PRI's mission is to enrich and broaden the education of ACP students. The Institute provides hands-on access to the full spectrum of drug development, showing rather than just telling how medicines advance "from the bench to the bedside" and presenting students with a broad array of career options.

With the cutting-edge world of pharmaceutical R&D at their fingertips, faculty and students truly can go anywhere their interests and imaginations can take them.



Partnerships and Collaborations

The collaborative spirit emerging as the driving force in scientific discovery guides the research environment at PRI. The Institute strives to form collaborative research efforts as it seeks out new and better ways to solve medical questions. PRI partners with academic institutes and pharmaceutical and biotechnology companies worldwide.

Biotechnology + Nanotechnology = NanoPharmaceuticals

Through the development of the Center for NanoPharmaceuticals, PRI is a leader in this rapidly emerging area. With its focused drug discovery and drug development, PRI advances the utility of nanotechnology and biotechnology in accelerating novel discoveries and development.

Preformulation and Stability Testing

An important strategic focus for PRI is its preformulation and stability testing laboratories to facilitate drug development for pharmaceutical and biotechnology institutes. This arm of PRI works with pharmaceutical companies locally, regionally, nationally and worldwide to manufacture small and medium batches of drugs, providing a cost-effective way for companies to further expand the depth and breadth of their drug development activities.





Experimental Research

This component focuses on identifying novel therapeutic and diagnostic strategies for unmet medical needs, specializing in In Vitro and In Vivo models of angiogenesis, thrombosis and vascular biology. Through this component, PRI seeks to spin off new business ventures to focus on developing and marketing certain products. The first of these start-up companies, Angiopharma Inc., was formed in 2002. Based on patents held by the Institute's Executive Vice President and Chairman, Shaker Mousa, Ph.D., Angiopharma is focused on drug development related to macular degeneration and cancer.



Clinical Monitoring and Screening

PRI strives to establish novel and routine surrogate biochemical, genetic and immuno-histological markers for drug discovery and early clinical development. These clinical monitoring and screening capabilities allow PRI to provide key information that bridges the gap between experimental and clinical results. Mechanism-related readouts are essential in the prediction of successful clinical outcomes using surrogates or biomarkers. PRI utilizes high throughput screening for novel pro- and anti-genesis leads, anti-integrins, anti-thrombotics (anti-platelets and anti-coagulants) and vessel wall passivation mechanisms. Additionally, PRI will acquire chemical libraries (small molecule, peptidomimetic, natural products) through partnerships, co-patents and licensing arrangements.



**The Future of
Discovery
and Drug
Development**

Pharmaceutical Research Institute at Albany College of Pharmacy
106 New Scotland Avenue, Albany, NY 12208-3492
T/ 518 694 7397 F/ 518 694 7392 www.pri-albany.org

**The future of drug development
– indeed the future of medical
science – is alive with infinite
and unprecedented
opportunities.**



ADVANCING NOVEL MEDICINES

Check your watch. Imagine that instead of the time, you are checking the levels of a cancer antigen in your blood, but without breaking the skin. The small piece of equipment strapped around your wrist is a noninvasive biosensor; implanted with a specific cancer antibody. The equipment is so sensitive that it can detect the presence of a single cancer cell in your blood.


The future of drug discovery and development – indeed, the future of all medical science – is alive with infinite and unprecedented opportunities to cure, heal and ultimately unlock the mysteries concealed within the very flesh, bone and fiber of the human body.

The vision of the Pharmaceutical Research Institute at Albany College of Pharmacy is to advance novel medicines for vascular, oncological and ophthalmological disorders. We focus on serving patients and health care providers with our scientific capabilities, which include the merger of nanotechnology and biotechnology through our Center for NanoPharmaceuticals. Our primary mission is to promote the advancement of pharmaceutical sciences as an integral component of medical care, and to use our knowledge and vision to enrich our academic environment.

PRI's research laboratories strive to provide the foundation necessary to introduce innovative, noninvasive diagnostic methods. These modalities will aid in disease definition and in monitoring the influence of therapy on disease progression. Overall, our pioneering use of nanopharmaceutical technology will accelerate drug discovery and development. With Ph.D.- and M.S.-level scientists building a multilayered repository of scientific expertise, PRI is a vital member of New York State's growing biomedical research sector; a cutting-edge community of leaders who share one goal – a healthier world.

At PRI, the possibilities are endless. We invite you to join us on this exciting journey into the future of drug discovery and development.




Shaker A. Mousa, Ph.D., MBA
Executive Vice President
and Chairman